176 related articles for article (PubMed ID: 32606830)
1. A Systematic Review of Vancomycin Dosing in Patients with Hematologic Malignancies or Neutropenia.
He N; Dong F; Liu W; Zhai S
Infect Drug Resist; 2020; 13():1807-1821. PubMed ID: 32606830
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic model and dosing optimization of vancomycin in hematologic malignancies with neutropenia and augmented renal clearance.
Belabbas T; Yamada T; Egashira N; Hirota T; Suetsugu K; Mori Y; Kato K; Akashi K; Ieiri I
J Infect Chemother; 2023 Apr; 29(4):391-400. PubMed ID: 36682608
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies.
Fernández de Gatta MD; Calvo MV; Hernández JM; Caballero D; San Miguel JF; Domínguez-Gil A
Clin Pharmacol Ther; 1996 Sep; 60(3):332-40. PubMed ID: 8841156
[TBL] [Abstract][Full Text] [Related]
4. Augmented Renal Clearance and Hypoalbuminemia-Induced Low Vancomycin Trough Concentrations in Febrile Neutropenic Patients With Hematological Malignancies.
Alzahrani AM; Hakami AY; AlAzmi A; Karim S; Ali AS; Burzangi AS; Alkreathy HM; Khan MA; Alzhrani RM; Basudan SS; Alzahrani YA
Cureus; 2022 Sep; 14(9):e29568. PubMed ID: 36312611
[TBL] [Abstract][Full Text] [Related]
5. Vancomycin dosing in neutropenic patients.
Haeseker MB; Croes S; Neef C; Bruggeman CA; Stolk LM; Verbon A
PLoS One; 2014; 9(11):e112008. PubMed ID: 25390637
[TBL] [Abstract][Full Text] [Related]
6. Individualized dosing of vancomycin in geriatric patients.
Suchánková H; Lečbychová K; Strojil J; Fürst T
Epidemiol Mikrobiol Imunol; 2020; 69(4):172-180. PubMed ID: 33445941
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetic Models of Vancomycin in Paediatric Patients: A Systematic Review.
Chung E; Sen J; Patel P; Seto W
Clin Pharmacokinet; 2021 Aug; 60(8):985-1001. PubMed ID: 34002357
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Vancomycin Prediction Methods Based on Estimated Creatinine Clearance or Trough Levels.
Haeseker M; Croes S; Neef C; Bruggeman C; Stolk L; Verbon A
Ther Drug Monit; 2016 Feb; 38(1):120-6. PubMed ID: 26418699
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of Teicoplanin and Its Dosing Recommendations for Neutropenic Patients With Augmented Renal Clearance for Hematological Malignancies.
Sako KI; Nakamaru Y; Ikawa K; Maeda T; Goto S; Ishihara Y; Kato Y; Matsuda Y
Ther Drug Monit; 2021 Aug; 43(4):519-526. PubMed ID: 34250964
[TBL] [Abstract][Full Text] [Related]
10. A retrospective analysis to estimate target trough concentration of vancomycin for febrile neutropenia in patients with hematological malignancy.
Suzuki Y; Tokimatsu I; Morinaga Y; Sato Y; Takano K; Kohno K; Ogata M; Hiramatsu K; Itoh H; Kadota J
Clin Chim Acta; 2015 Feb; 440():183-7. PubMed ID: 25476135
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Cefepime in Patients with Cancer and Febrile Neutropenia in the Setting of Hematologic Malignancies or Hematopoeitic Cell Transplantation.
Whited L; Grove M; Rose D; Rhodes NJ; Scheetz MH; O'Donnell JN; Neeb J; Thoele K; Jones DR; Lowe C; Moore D; Kiel PJ
Pharmacotherapy; 2016 Sep; 36(9):1003-10. PubMed ID: 27496678
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Pharmacokinetic Outcomes of Peak-Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug Monitoring Approaches: A Pragmatic Randomized Controlled Trial.
Al-Sulaiti FK; Nader AM; Saad MO; Shaukat A; Parakadavathu R; Elzubair A; Al-Badriyeh D; Elewa H; Awaisu A
Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):639-652. PubMed ID: 30919233
[TBL] [Abstract][Full Text] [Related]
13. The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults.
Bury D; Ter Heine R; van de Garde EMW; Nijziel MR; Grouls RJ; Deenen MJ
Eur J Clin Pharmacol; 2019 Jul; 75(7):921-928. PubMed ID: 30877327
[TBL] [Abstract][Full Text] [Related]
14. The Benefit of Individualized Vancomycin Dosing Via Pharmacokinetic Tools: A Systematic Review and Meta-analysis.
He N; Su S; Yan Y; Liu W; Zhai S
Ann Pharmacother; 2020 Apr; 54(4):331-343. PubMed ID: 31694384
[No Abstract] [Full Text] [Related]
15. [Research of optimal dosing regimens and therapeutic drug monitoring for vancomycin by clinical pharmacists: analysis of 7-year data].
Xu G; Chen E; Mao E; Che Z; He J
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Jul; 30(7):640-645. PubMed ID: 30045790
[TBL] [Abstract][Full Text] [Related]
16. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program.
Menichetti F; Martino P; Bucaneve G; Gentile G; D'Antonio D; Liso V; Ricci P; Nosari AM; Buelli M; Carotenuto M
Antimicrob Agents Chemother; 1994 Sep; 38(9):2041-6. PubMed ID: 7811016
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of vancomycin in paediatric patients with febrile neutropenia and augmented renal clearance: development of new dosing recommendations.
Shimamoto Y; Verstegen RHJ; Mizuno T; Schechter T; Allen U; Ito S
J Antimicrob Chemother; 2021 Oct; 76(11):2932-2940. PubMed ID: 34480578
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease.
Zhao W; Zhang D; Fakhoury M; Fahd M; Duquesne F; Storme T; Baruchel A; Jacqz-Aigrain E
Antimicrob Agents Chemother; 2014 Jun; 58(6):3191-9. PubMed ID: 24663023
[TBL] [Abstract][Full Text] [Related]
19. Utilization of cefepime therapeutic drug monitoring in febrile neutropenia patients with hematologic malignancies.
Lodl EF; Alshaer MH; Adams CB; Richards A; Peloquin C; Venugopalan V
J Oncol Pharm Pract; 2023 Nov; ():10781552231213883. PubMed ID: 37981806
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.
Waineo MF; Kuhn TC; Brown DL
J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
